Sangamo Shares Plummet as Pfizer Ends Partnership
Sangamo Therapeutics stock drops 50% following Pfizer's termination of their co-development agreement. Discover the impact on Sangamo's future prospects.
Topic
biotech
A collection of 25 issues
Pfizer Shares Rise Amid Sangamo Partnership Termination
Pfizer shares slightly increased despite ending its collaboration with Sangamo. Explore what this means for investors and the future of biotech cooperation.
Sangamo Shares Plunge as Pfizer Exits Partnership
Sangamo Therapeutics' stock plummeted by over 50% following Pfizer's decision to withdraw from their joint agreement. Explore the impact on biotech stocks.
Sangamo Shares Plummet After Pfizer Ends Collaboration
Sangamo Therapeutics' stock nosedives over 50% as Pfizer halts partnership on hemophilia drug. Discover the implications for Sangamo's future and investor concerns.
Pfizer Ends Partnership with Sangamo on Hemophilia A Therapy
Pfizer terminates its partnership with Sangamo, citing limited interest in advancing another hemophilia A gene therapy. Explore the implications for biotech innovation.
Pfizer's Withdrawal Hits Sangamo with Negative Sentiment
Explore the impact of Pfizer's withdrawal on Sangamo, leading to negative market sentiment. Key insights into biotech market dynamics.
Pfizer Opts Out of New Hemophilia A Gene Therapy
Pfizer pulls back on developing a new gene therapy for hemophilia A, citing limited market interest. Explore the implications for the hemophilia community and biotech sector.
Sangamo's Market Value Nears $500 Million
Discover how Sangamo's market value was just below $500 million before recent developments. Stay updated on biotech market trends and company valuations.
Biotech Sector Faces Partnership and Development Risks
Explore the biotech sector's challenges with partnerships and drug development risks. Discover the industry's latest trends and potential solutions.
Roche Maintains Steady Workforce Amid Economic Uncertainty
Roche's workforce remains steady with slight growth, signaling stability and no imminent layoffs. Explore the implications for the biotech giant's future.